Analysis of UGT1A's polymorphisms and RAS: RAF mutations based on phase II study of biweekly XELIRI plus bevacizumab as a second-line therapy in patients with metastatic colorectal cancer

Hiroaki Tanioka
Nobuaki Suzuki
Shoichi Hazama
Takeshi Nagasaka
Yasuo Iwamoto
Yuji Negoro
Yuki Nakagami
Ryouichi Tsunedomi
Hiroaki Nagano
Masazumi Okajima

JOURNAL OF CLINICAL ONCOLOGY

37

4

10.1200/JCO.2019.37.4_suppl.565

https://doi.org/10.1200/JCO.2019.37.4_suppl.565
https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=JSTA_CEL&SrcApp=J_Gate_JST&DestLinkType=FullRecord&KeyUT=WOS:000489107600570&DestApp=WOS_CPL